The present invention relates to a method for drying human milk oligosaccharides (HMOs). More specifically, the present invention is related to a method of roller drying or drum drying of human milk oligosaccharides in a simple and economical way.

The present invention relates to a method for drying human milk oligosaccharides (HMOs). More specifically, the present invention is related to a method of roller drying or drum drying of human milk oligosaccharides in a simple and economical way.

The present invention relates to an enteral sustained-release sugar alcohol additive including an inner layer structure and an outer layer structure. The inner layer structure contains components of xylitol and agar, and the outer layer structure contains components of carrageenan or gellan gum or xanthan gum or guar gum, vitamin B12, L-arabinose, and fermented bifidobacterium or fermented propionibacterium or fermented lactobacillus. The present invention further provides a method of preparing an enteral sustained-release sugar alcohol additive and an application thereof. In the present invention, by compounding xylitol, L-arabinose and vitamin B12, directional regulation of intestinal microorganisms can be achieved and high concentration synthesis of propionate in the intestine can be realized.

The present invention relates to an enteral sustained-release sugar alcohol additive including an inner layer structure and an outer layer structure. The inner layer structure contains components of xylitol and agar, and the outer layer structure contains components of carrageenan or gellan gum or xanthan gum or guar gum, vitamin B12, L-arabinose, and fermented bifidobacterium or fermented propionibacterium or fermented lactobacillus. The present invention further provides a method of preparing an enteral sustained-release sugar alcohol additive and an application thereof. In the present invention, by compounding xylitol, L-arabinose and vitamin B12, directional regulation of intestinal microorganisms can be achieved and high concentration synthesis of propionate in the intestine can be realized.

A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.

The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1.fwdarw.4)-galacturonic-alpha(1.fwdarw.2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.

The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1.fwdarw.4)-galacturonic-alpha(1.fwdarw.2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.

The present invention relates to formulae for infants born to a mother that is overweight or obese at the time of conception of the infant for improving the postnatal growth trajectory or body development.

The present invention relates to formulae for infants born to a mother that is overweight or obese at the time of conception of the infant for improving the postnatal growth trajectory or body development.

Disclosed is a jelly-like food composition comprising an extract of a Kampo bulk drug, a sweetening agent, a gelling agent, an acidulant, and a flavor.